A committee of the European Medicines Agency (EMA) has recommended the approval of Ipsen‘s tovorafenib for the treatment of…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
GYNECOLOGICAL CANCER
New trial data show alnodesertib may slow ovarian cancer progression
A low dose of alnodesertib added to standard chemotherapy significantly reduced the likelihood of disease progression among people with platinum-resistant…
Early results from the Phase 2/3 MIRACLE clinical trial suggest that the experimental chemotherapy drug annamycin may offer meaningful benefit…
A new blood test powered by artificial intelligence (AI) could offer a life-saving head start for patients at high risk…
An “immuno-gene” therapy that turns a virus into a cancer-fighting agent has received a fast-track designation from the U.S. Food…
GYNECOLOGICAL CANCER
FDA approves Keytruda for hard-to-treat gynecological cancers
People in the U.S. with certain gynecological cancers that are resistant to first-line chemotherapies now have a new treatment option:…
The U.S. Food and Drug Administration (FDA) is reviewing an application from Bristol Myers Squibb (BMS) seeking approval of…
The U.S. Food and Drug Administration (FDA) has approved the combination of two oral therapies, Venclexta (venetoclax) and Calquence (acalabrutinib),…
PANCREATIC CANCER
Pancreatic cancer growth tied to cells’ self-eating process
A cellular recycling process called autophagy helps determine whether pancreatic cancer cells grow quickly or hunker into survival mode…
Telix Pharmaceuticals has submitted an application to European regulators seeking approval for TLX101-Px, the company’s experimental imaging agent designed…